Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aptose Biosciences Inc.

Get SEC filing alerts via email and in your feed for Aptose Biosciences Inc.

APTO APTOF

Aptose Biosciences Inc.

About Aptose Biosciences Inc.

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision small molecule therapies for hematologic cancers, primarily acute myeloid leukemia (AML) and related blood malignancies. Its pipeline includes oral kinase inhibitors tuspetinib and luxeptinib, designed to target key oncogenic pathways with improved safety profiles. Aptose aims to address unmet medical needs through targeted therapies that enhance efficacy and overcome resistance in diverse patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aptose Biosciences Inc.

1
1
Aptose Biosciences Inc. Aptose Biosciences Reports $7.6 Million Net Loss in Q1 2026, Faces Financial Challenges

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Aptose Biosciences Inc. Aptose Biosciences Reports $25.5 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Aptose Biosciences Inc. Aptose Biosciences Reports $17.7 Million Net Loss for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aptose Biosciences Inc. Aptose Biosciences Reports $12.6 Million Net Loss and Faces Financial Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aptose Biosciences Inc. Aptose Biosciences Reports $5.5 Million Net Loss and Pauses Luxeptinib Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aptose Biosciences Inc. Aptose Biosciences Reports $25.4 Million Net Loss for Fiscal Year 2024, Sees Decrease in R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Aptose Biosciences Inc. Aptose Biosciences Reports Improved Financial Results, Reduced Losses, and Increased Cash Flow Amid Challenges in Raising Additional Funds

Via official filing (AI summary) | over 1 year ago | 0 comments